Teladoc (TDOC) Q2 Revenue Tops Consensus, Offers Guidance

Go back to Teladoc (TDOC) Q2 Revenue Tops Consensus, Offers Guidance

Teladoc (TDOC) Falls 6% on Growing Losses and Weak Guidance to Prompt a Downgrade to 'Hold' at Deutsche Bank

July 28, 2021 10:01 AM EDT

Shares of Teladoc Health (NYSE: TDOC) are down more than 6% in todays trading session after the company presented disappointing Q2 results.

The company reported a loss of $0.86 per share while the surveyed analysts were expecting a loss of just $0.53 per share. Losses have more than doubled compared to $0.34 a year ago. Revenue grew 109% year-over-year to $503 million.

Teladoc Health delivered a strong second quarter, marked by exciting new client wins, product launches, and tremendous progress on our quest to be the category-defining provider of whole person virtual care, said Jason Gorevic, chief executive... More

Teladoc (TDOC) PT Lowered to $205 at Needham & Company

July 28, 2021 8:54 AM EDT

Needham & Company analyst Ryan MacDonald lowered the price target on Teladoc (NYSE: TDOC) to $205.00 (from $235.00) while maintaining a Buy rating.

The analyst commented, "We are reiterating our Buy rating, while lowering our PT to $205 following the company's solid 2Q in which organic growth remained... More

Teladoc (TDOC) PT Lowered to $185 at Cantor Fitzgerald

July 28, 2021 6:46 AM EDT

Cantor Fitzgerald analyst Steven Halper lowered the price target on Teladoc (NYSE: TDOC) to $185.00 (from $210.00) while maintaining a Neutral rating.

The analyst commented, "We reiterate our Neutral rating on TDOC shares and lower our price target to $185 from $210. After the market close on Tuesday, July 27, TDOC reported 2Q21 results. Revenue and... More